Laparoscopic partial hepatectomy is cost-effective when performed in high volume centers: A five state analysis - 12/08/21
, Patrick J. Sweigert a, Ruojia Debbie Li a, Paul C. Kuo b, Haroon Janjua b, Gerard Abood a, Marshall S. Baker aAbstract |
Background |
Prior studies comparing the efficacy of laparoscopic (LHR) and open hepatic resection (OHR) have not evaluated inpatient costs.
Methods |
We conducted a retrospective cohort study using the Healthcare Cost and Utilization Project State Inpatient Databases to identify patients undergoing hepatic resection between 2010 and 2014.
Results |
10,239 patients underwent hepatic resection. 865 (8%) underwent LHR and 9374 (92%) underwent OHR. On adjusting for hospital volume, patients undergoing LHR had a lower risk of respiratory (OR 0.64, 95% CI [0.52, 0.78]), wound (OR 0.48; 95% CI [0.29, 0.79]) and hematologic (OR 0.57; 95% CI [0.44, 0.73]) complication as well as a lower risk of being in the highest quartile of cost (0.58; 95% CI [0.43, 0.77]) than those undergoing OHR. Patients undergoing LHR in very high volume (>314 hepatectomies/year) centers had lower risk-adjusted 90-day aggregate costs of care than those undergoing OHR (-$8022; 95% CI [-$11,732, -$4311).
Discussion |
Laparoscopic partial hepatectomy is associated with lower risk of postoperative complication than OHR. This translates to lower aggregate costs in very high-volume centers.
El texto completo de este artículo está disponible en PDF.Highlights |
• | Laparoscopic partial hepatectomy has a lower risk of postoperative complications. |
• | Laparoscopic partial hepatectomy has a lower risk of being a high cost outlier. |
• | Laparoscopic partial hepatectomy in very high volume centers have lower 90-day aggregate costs of care. |
Keywords : Healthcare economics, Cost-volume, Laparoscopic surgery, Hepatectomy
Esquema
Vol 222 - N° 3
P. 577-583 - septembre 2021 Regresar al número
Artículo precedente
- Impact of cancer center accreditation on outcomes of patients undergoing resection for hepatocellular carcinoma: A SEER-Medicare analysis
- Diamantis I. Tsilimigras, J. Madison Hyer, Adrian Diaz, Dimitrios Moris, Alizeh Abbas, Mary Dillhoff, Jordan M. Cloyd, Aslam Ejaz, Joal D. Beane, Allan Tsung, Timothy M. Pawlik
- Travel distance and overall survival in hepatocellular cancer care
- Julie B. Siegel, Shelby Allen, Kathryn E. Engelhardt, Katherine A. Morgan, William P. Lancaster
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?